Treatment of cancer by systemic administration of dbait molecules

Abstract

The present invention relates to the use of a DBait molecules by systemic routes without any combination with an endosomolytic agent.

We claim: 
     
         1 . A method of treating ovarian cancer comprising the administration, by a parenteral systemic route selected from intraperitoneal and intravenous administration to a subject having an ovarian cancer, a nucleic acid molecule of the following formula: 
       
         
           
           
               
               
           
         
       
       wherein N is a deoxynucleotide, n is an integer from 15 to 195, the underlined N refers to a nucleotide having or not a modified phosphodiester backbone, L′ is a linker, C is the molecule facilitating endocytosis selected from a lipophilic molecule or a ligand which targets cell receptor enabling receptor mediated endocytosis, L is a linker, m is an integer being 0 or 1 and p is 1; wherein the nucleic acid is to be used without combined administration of any quinoline endosomolytic agent. 
     
     
         2 . The method according to  claim 1 , wherein the nucleic acid of formula (I) has one or several of the following features:
 N is a deoxynucleotide selected from the group consisting of A (adenine), C (cytosine), T (thymine) and G (guanine) and selected so as to avoid occurrence of a CpG dinucleotide and to have less than 80% sequence identity to any gene in a human genome; and/or   the linked L′ is selected from the group consisting of hexaethyleneglycol, tetradeoxythymidylate (T4) and 1,19-bis(phospho)-8-hydraza-2-hydroxy-4-oxa-9-oxo-nonadecane; and/or   m is 1 and L is a carboxamido polyethylene glycol; and/or   C is selected from the group consisting of a cholesterol, single or double chain fatty acids and a ligand which targets cell receptor.   
     
     
         3 . The method according to  claim 1 , wherein the nucleic acid molecule has one of the following formulae: 
       
         
           
           
               
               
           
         
       
       wherein the underlined nucleotide refers to a nucleotide having or not a phosphorothioate or methylphosphonate backbone, the linked L′ is selected from the group consisting of hexaethyleneglycol, tetradeoxythymidylate (T4) and 1,19-bis(phospho)-8-hydraza-2-hydroxy-4-oxa-9-oxo-nonadecane; m is 1 and L is a carboxamido oligoethylene glycol, C is selected from the group consisting of dioleoyl, octadecyl, folic acid, tocopherol and cholesterol. 
     
     
         4 . The method according to  claim 1 , wherein the nucleic acid is 
       
         
           
           
               
               
           
         
       
       and wherein the underlined nucleotide refers to a nucleotide having a phosphorothioate backbone, the linked L′ is 1,19-bis(phospho)-8-hydraza-2-hydroxy-4-oxa-9-oxo-nonadecane; m is 1 and L is a carboxamido tetraethylene glycol, C is cholesterol. 
     
     
         5 . The method according to  claim 1 , wherein the nucleic acid is to be administered by intravenous route. 
     
     
         6 . The method according to  claim 5 , wherein the nucleic acid is to be administered by injection, intravenous drip, bolus or pump. 
     
     
         7 . The method according to  claim 1 , wherein the nucleic acid is administered in combination with antitumor treatment. 
     
     
         8 . The method according to  claim 1 , wherein the nucleic acid is administered in combination with radiotherapy and/or chemotherapy. 
     
     
         9 . The method according to  claim 1 , wherein the nucleic acid is administered in combination with a DNA damaging anti-tumor agent. 
     
     
         10 . The method according to  claim 9 , wherein the DNA damaging anti-tumor agent is selected from the group consisting of an inhibitor of topoisomerases I or II, a DNA crosslinker, a DNA alkylating agent, an anti-metabolic agent and inhibitors of the mitotic spindles. 
     
     
         11 . The method according to  claim 1 , wherein the nucleic acid is to be used in combination with a platinum drug selected from the group consisting of oxaliplatin, carboplatin and cisplatin. 
     
     
         12 . The method according to  claim 2 , wherein L is carboxamido triethylene or tetraethylene glycol. 
     
     
         13 . The method according to  claim 2 , wherein C is selected from the group consisting of octadecyl, oleic acid, dioleoyl acid, stearic acid, tocopherol, cholesterol, folic acid, galactose, mannose, oligosaccharide of galactose and/or mannose, RGD, bombesin, integrin and transferrin.